TMCnet - World's Largest Communications and Technology Community



Respiratory Tract Infections - Pipeline Review, H2 2012 Features Giants such as Merck & Co., Inc., Bayer AG and Novartis AG
[December 17, 2012]

Respiratory Tract Infections - Pipeline Review, H2 2012 Features Giants such as Merck & Co., Inc., Bayer AG and Novartis AG

Dec 17, 2012 (M2 PRESSWIRE via COMTEX) -- Research and Markets ( has announced the addition of Global Markets Direct's new report "Respiratory Tract Infections - Pipeline Review, H2 2012" to their offering.

Global Markets Direct's, 'Respiratory Tract Infections - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Respiratory Tract Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Tract Infections. Respiratory Tract Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope - A snapshot of the global therapeutic scenario for Respiratory Tract Infections.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Respiratory Tract Infections pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Aradigm Corporation Shionogi & Co., Ltd.

Sanofi-Aventis GlaxoSmithKline plc Daiichi Sankyo Company, Ltd Taisho Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Company Limited Nanotherapeutics, Inc.

Rib-X Pharmaceuticals, Inc.

Nippon Shinyaku Co., Ltd.

Zosano Pharma, Inc.

Insmed Incorporated Dongwha Pharm Co., Ltd.

Green Cross Corporation iBio, Inc.

Tetraphase Pharmaceuticals Inc.

Afexa Life Sciences Inc.

For more information visit Source: Global Markets Direct CONTACT: Research and Markets, Laura Wood, Senior Manager. Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 Sector: Respiratory ( cat_id=75&campaign_id=5lhv6v) ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at on the world wide web. Inquiries to

[ Back To's Homepage ]

ITEXPO 2016 begins in:





Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2015 Technology Marketing Corporation. All rights reserved | Privacy Policy